Diffuse Gonococcal Infection (DGI) in a Patient with Treatment-Refractory Acetylcholine Receptor Antibody-Positive (AChR+) Generalized Myasthenia Gravis (gMG) Treated with Eculizumab.

IF 0.9 Q4 CLINICAL NEUROLOGY
Case Reports in Neurological Medicine Pub Date : 2021-06-14 eCollection Date: 2021-01-01 DOI:10.1155/2021/9713413
Nakul Katyal, Latika Nirola, Naureen Narula, Raghav Govindarajan
{"title":"Diffuse Gonococcal Infection (DGI) in a Patient with Treatment-Refractory Acetylcholine Receptor Antibody-Positive (AChR+) Generalized Myasthenia Gravis (gMG) Treated with Eculizumab.","authors":"Nakul Katyal,&nbsp;Latika Nirola,&nbsp;Naureen Narula,&nbsp;Raghav Govindarajan","doi":"10.1155/2021/9713413","DOIUrl":null,"url":null,"abstract":"<p><p>Patients receiving complement inhibitor, eculizumab, are at high risk for infections with encapsulated organisms such as <i>Neisseria</i> due to impaired opsonophagocytic activity. Impaired complement immunity may increase the risk for dissemination of asymptomatic <i>Neisseria gonorrhoeae</i>. Disseminated Gonococcal Infection (DGI) is a rare but potentially life-threatening complication associated with eculizumab. Physicians should obtain adequate sexual histories from the patients and educate them on safe sexual practices. Here, we describe a case of DGI in a 32-year-old African American female patient with acetylcholine receptor antibody-positive (AChR+) generalized myasthenia gravis (gMG), receiving eculizumab.</p>","PeriodicalId":9615,"journal":{"name":"Case Reports in Neurological Medicine","volume":" ","pages":"9713413"},"PeriodicalIF":0.9000,"publicationDate":"2021-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216817/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Neurological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/9713413","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Patients receiving complement inhibitor, eculizumab, are at high risk for infections with encapsulated organisms such as Neisseria due to impaired opsonophagocytic activity. Impaired complement immunity may increase the risk for dissemination of asymptomatic Neisseria gonorrhoeae. Disseminated Gonococcal Infection (DGI) is a rare but potentially life-threatening complication associated with eculizumab. Physicians should obtain adequate sexual histories from the patients and educate them on safe sexual practices. Here, we describe a case of DGI in a 32-year-old African American female patient with acetylcholine receptor antibody-positive (AChR+) generalized myasthenia gravis (gMG), receiving eculizumab.

Eculizumab治疗难治性乙酰胆碱受体抗体阳性(AChR+)广泛性重症肌无力(gMG)患者的弥漫性淋球菌感染(DGI)
由于调理吞噬活性受损,接受补体抑制剂eculizumab治疗的患者感染被包膜生物(如奈瑟菌)的风险很高。补体免疫受损可能增加无症状淋病奈瑟菌传播的风险。播散性淋球菌感染(DGI)是一种罕见但可能危及生命的并发症,与eculizumab相关。医生应该从病人那里获得足够的性史,并教育他们安全的性行为。在这里,我们描述了一个32岁的非裔美国女性患者的DGI乙酰胆碱受体抗体阳性(AChR+)全身性重症肌无力(gMG),接受eculizumab。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
26
审稿时长
11 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信